Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Videos|June 17, 2019
Creating a Leadership Legacy for Women in Pharmacy
In this video, sponsored by Cardinal Health, female pharmacists and pharmacy owners discuss what makes a good leader and how they would leave a legacy of leadership in their communities.
Advertisement
In this video, sponsored by Cardinal Health, female pharmacists and pharmacy owners discuss what makes a good leader and how they would leave a legacy of leadership in their communities.
Advertisement
Related to this article
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5